Cencora, Inc. (NYSE:COR) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Cencora, Inc. (NYSE:COR) have been given an average rating of “Moderate Buy” by the fifteen research firms that are currently covering the company, Marketbeat reports. Three investment analysts have rated the stock with a hold recommendation and twelve have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $367.75.

COR has been the topic of a number of recent research reports. UBS Group upped their target price on Cencora from $410.00 to $412.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Weiss Ratings downgraded Cencora from a “buy (b)” rating to a “buy (b-)” rating in a research note on Friday, May 22nd. Bank of America upped their target price on Cencora from $280.00 to $285.00 and gave the stock a “neutral” rating in a research note on Wednesday. Leerink Partners restated an “outperform” rating on shares of Cencora in a research note on Tuesday, March 17th. Finally, Wells Fargo & Company lowered their price target on shares of Cencora from $429.00 to $331.00 and set an “overweight” rating on the stock in a report on Monday, May 11th.

Cencora Stock Up 0.0%

COR stock opened at $286.97 on Tuesday. The firm’s fifty day simple moving average is $280.84 and its 200-day simple moving average is $322.18. The company has a market capitalization of $55.83 billion, a P/E ratio of 22.01, a price-to-earnings-growth ratio of 1.59 and a beta of 0.59. The company has a debt-to-equity ratio of 3.40, a current ratio of 0.95 and a quick ratio of 0.59. Cencora has a 12 month low of $244.82 and a 12 month high of $377.54.

Cencora (NYSE:COR) last released its quarterly earnings data on Wednesday, May 6th. The company reported $4.75 EPS for the quarter, missing the consensus estimate of $4.82 by ($0.07). The business had revenue of $78.36 billion during the quarter, compared to analysts’ expectations of $81.09 billion. Cencora had a net margin of 0.78% and a return on equity of 135.20%. The firm’s revenue was up 3.9% on a year-over-year basis. During the same period last year, the company earned $4.42 earnings per share. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. As a group, equities research analysts forecast that Cencora will post 17.79 earnings per share for the current year.

Cencora Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, June 1st. Investors of record on Friday, May 15th were issued a dividend of $0.60 per share. The ex-dividend date of this dividend was Friday, May 15th. This represents a $2.40 dividend on an annualized basis and a yield of 0.8%. Cencora’s dividend payout ratio is 18.40%.

Cencora declared that its Board of Directors has initiated a share repurchase program on Thursday, May 21st that allows the company to buyback $2.00 billion in outstanding shares. This buyback authorization allows the company to reacquire up to 3.9% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s management believes its stock is undervalued.

Insider Transactions at Cencora

In other Cencora news, Director Lauren M. Tyler purchased 550 shares of the stock in a transaction on Monday, June 22nd. The shares were bought at an average price of $270.23 per share, for a total transaction of $148,626.50. Following the completion of the transaction, the director owned 4,359 shares of the company’s stock, valued at $1,177,932.57. This trade represents a 14.44% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Corporate insiders own 0.38% of the company’s stock.

Hedge Funds Weigh In On Cencora

A number of hedge funds have recently bought and sold shares of the business. T. Rowe Price Investment Management Inc. lifted its holdings in Cencora by 160.1% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 6,700,091 shares of the company’s stock valued at $2,262,956,000 after purchasing an additional 4,123,795 shares in the last quarter. Norges Bank purchased a new position in Cencora during the fourth quarter valued at $822,506,000. Marshall Wace LLP lifted its holdings in Cencora by 518.9% during the third quarter. Marshall Wace LLP now owns 1,995,118 shares of the company’s stock valued at $623,534,000 after purchasing an additional 1,672,762 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Cencora by 528.9% during the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,475,859 shares of the company’s stock valued at $461,250,000 after purchasing an additional 1,241,186 shares in the last quarter. Finally, Viking Global Investors LP lifted its holdings in Cencora by 95.0% during the second quarter. Viking Global Investors LP now owns 2,081,732 shares of the company’s stock valued at $624,207,000 after purchasing an additional 1,013,913 shares in the last quarter. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.